Analysis of advanced melanomas changed from immune checkpoint blockade therapy to palliative care

Ai Kajita, Osamu Yamasaki, Tatsuya Kaji, Hiroshi Umemura, Keiji Iwatsuki

Research output: Contribution to journalArticle

Abstract

New treatments for advanced melanoma such as immune checkpoint blockades contribute to an improved long-term survival of the disease. However, the response evaluation of immune checkpoint blockades is difficult, and the decision about when to stop the drug in progressive disease (PD) cases is difficult, too. We analyzed 8 patients with advanced melanoma who changed to palliative care following immune checkpoint blockade (nivolumab or ipilimumab) between July 2014 and June 2016. Two of the patients were male and 6 were female. The mean age was 69.3 years. The BRAF V600E mutation was not detected in 6 patients. The mean number of administrations and period of the immune checkpoint blockades from PD determination to the last dosage were 2.4 times and 36.1 days, respectively. The mean period from the last dosage to death was 36.1 days. We should change from immune checkpoint blockade to another treatment or palliative care in PD cases, but we often continued it beyond PD when there was no other treatment available.

Original languageEnglish
Pages (from-to)51-55
Number of pages5
JournalNishinihon Journal of Dermatology
Volume80
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Palliative Care
Melanoma
Therapeutics
Mutation
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Dermatology

Cite this

Analysis of advanced melanomas changed from immune checkpoint blockade therapy to palliative care. / Kajita, Ai; Yamasaki, Osamu; Kaji, Tatsuya; Umemura, Hiroshi; Iwatsuki, Keiji.

In: Nishinihon Journal of Dermatology, Vol. 80, No. 1, 01.01.2018, p. 51-55.

Research output: Contribution to journalArticle

@article{1b99f33149e44cb88483c6c126f3384b,
title = "Analysis of advanced melanomas changed from immune checkpoint blockade therapy to palliative care",
abstract = "New treatments for advanced melanoma such as immune checkpoint blockades contribute to an improved long-term survival of the disease. However, the response evaluation of immune checkpoint blockades is difficult, and the decision about when to stop the drug in progressive disease (PD) cases is difficult, too. We analyzed 8 patients with advanced melanoma who changed to palliative care following immune checkpoint blockade (nivolumab or ipilimumab) between July 2014 and June 2016. Two of the patients were male and 6 were female. The mean age was 69.3 years. The BRAF V600E mutation was not detected in 6 patients. The mean number of administrations and period of the immune checkpoint blockades from PD determination to the last dosage were 2.4 times and 36.1 days, respectively. The mean period from the last dosage to death was 36.1 days. We should change from immune checkpoint blockade to another treatment or palliative care in PD cases, but we often continued it beyond PD when there was no other treatment available.",
author = "Ai Kajita and Osamu Yamasaki and Tatsuya Kaji and Hiroshi Umemura and Keiji Iwatsuki",
year = "2018",
month = "1",
day = "1",
doi = "10.2336/nishinihonhifu.80.51",
language = "English",
volume = "80",
pages = "51--55",
journal = "Nishinihon Journal of Dermatology",
issn = "0386-9784",
publisher = "Kyushu University, Faculty of Science",
number = "1",

}

TY - JOUR

T1 - Analysis of advanced melanomas changed from immune checkpoint blockade therapy to palliative care

AU - Kajita, Ai

AU - Yamasaki, Osamu

AU - Kaji, Tatsuya

AU - Umemura, Hiroshi

AU - Iwatsuki, Keiji

PY - 2018/1/1

Y1 - 2018/1/1

N2 - New treatments for advanced melanoma such as immune checkpoint blockades contribute to an improved long-term survival of the disease. However, the response evaluation of immune checkpoint blockades is difficult, and the decision about when to stop the drug in progressive disease (PD) cases is difficult, too. We analyzed 8 patients with advanced melanoma who changed to palliative care following immune checkpoint blockade (nivolumab or ipilimumab) between July 2014 and June 2016. Two of the patients were male and 6 were female. The mean age was 69.3 years. The BRAF V600E mutation was not detected in 6 patients. The mean number of administrations and period of the immune checkpoint blockades from PD determination to the last dosage were 2.4 times and 36.1 days, respectively. The mean period from the last dosage to death was 36.1 days. We should change from immune checkpoint blockade to another treatment or palliative care in PD cases, but we often continued it beyond PD when there was no other treatment available.

AB - New treatments for advanced melanoma such as immune checkpoint blockades contribute to an improved long-term survival of the disease. However, the response evaluation of immune checkpoint blockades is difficult, and the decision about when to stop the drug in progressive disease (PD) cases is difficult, too. We analyzed 8 patients with advanced melanoma who changed to palliative care following immune checkpoint blockade (nivolumab or ipilimumab) between July 2014 and June 2016. Two of the patients were male and 6 were female. The mean age was 69.3 years. The BRAF V600E mutation was not detected in 6 patients. The mean number of administrations and period of the immune checkpoint blockades from PD determination to the last dosage were 2.4 times and 36.1 days, respectively. The mean period from the last dosage to death was 36.1 days. We should change from immune checkpoint blockade to another treatment or palliative care in PD cases, but we often continued it beyond PD when there was no other treatment available.

UR - http://www.scopus.com/inward/record.url?scp=85048520152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048520152&partnerID=8YFLogxK

U2 - 10.2336/nishinihonhifu.80.51

DO - 10.2336/nishinihonhifu.80.51

M3 - Article

AN - SCOPUS:85048520152

VL - 80

SP - 51

EP - 55

JO - Nishinihon Journal of Dermatology

JF - Nishinihon Journal of Dermatology

SN - 0386-9784

IS - 1

ER -